Dementia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 27: | Line 27: | ||
This category includes [[vitamin E]] and [[selegiline]] <ref name="pmid9110909">{{cite journal |vauthors=Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ |title=A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study |journal=N Engl J Med |volume=336 |issue=17 |pages=1216–22 |date=April 1997 |pmid=9110909 |doi=10.1056/NEJM199704243361704 |url=}}</ref> | This category includes [[vitamin E]] and [[selegiline]] <ref name="pmid9110909">{{cite journal |vauthors=Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ |title=A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study |journal=N Engl J Med |volume=336 |issue=17 |pages=1216–22 |date=April 1997 |pmid=9110909 |doi=10.1056/NEJM199704243361704 |url=}}</ref> | ||
They have modest benefit in delaying functional progression in patients with mild to moderate Alzheimer Disease. High dose Vitamin E is associated with an increase in all-cause mortality and also with heart failure in patients with cardiovascular disease.<ref name="pmid24381967">{{cite journal |vauthors=Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD |title=Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial |journal=JAMA |volume=311 |issue=1 |pages=33–44 |date=January 2014 |pmid=24381967 |pmc=4109898 |doi=10.1001/jama.2013.282834 |url=}}</ref> There is some beneficial effect of [[selegiline]] in the treatment of cognitive benefits and in the treatment of behavior and mood in some studies.<ref name="pmid9110909">{{cite journal |vauthors=Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ |title=A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study |journal=N Engl J Med |volume=336 |issue=17 |pages=1216–22 |date=April 1997 |pmid=9110909 |doi=10.1056/NEJM199704243361704 |url=}}</ref> | They have modest benefit in delaying functional progression in patients with mild to moderate Alzheimer Disease. High dose Vitamin E is associated with an increase in all-cause mortality and also with heart failure in patients with cardiovascular disease.<ref name="pmid24381967">{{cite journal |vauthors=Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD |title=Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial |journal=JAMA |volume=311 |issue=1 |pages=33–44 |date=January 2014 |pmid=24381967 |pmc=4109898 |doi=10.1001/jama.2013.282834 |url=}}</ref> There is some beneficial effect of [[selegiline]] in the treatment of cognitive benefits and in the treatment of behavior and mood in some studies.<ref name="pmid9110909">{{cite journal |vauthors=Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ |title=A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study |journal=N Engl J Med |volume=336 |issue=17 |pages=1216–22 |date=April 1997 |pmid=9110909 |doi=10.1056/NEJM199704243361704 |url=}}</ref> <ref name="pmid7700465">{{cite journal |vauthors=Potter LT |title=Discovery of treatments for Alzheimer's disease |journal=Neurobiol Aging |volume=15 Suppl 2 |issue= |pages=S67–9 |date=1994 |pmid=7700465 |doi=10.1016/0197-4580(94)90173-2 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 00:54, 7 October 2020
|
Dementia Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
The mainstay of management of dementia is :
- Symptomatic
- Treatment of behavioral disturbances
- Environmental manipulations to support function
- Counseling with respect to safety issues.
More precise diagnosis is required for effective management and accurate prognosis. Medical therapy for dementia include:
They increase cholinergic transmission by inhibiting cholinesterase at the synaptic cleft and provide modest symptomatic benefit in some patients with dementia.
Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia.
They have modest benefits in patients with moderate to severe AD[2]
This category includes vitamin E and selegiline [3]
They have modest benefit in delaying functional progression in patients with mild to moderate Alzheimer Disease. High dose Vitamin E is associated with an increase in all-cause mortality and also with heart failure in patients with cardiovascular disease.[4] There is some beneficial effect of selegiline in the treatment of cognitive benefits and in the treatment of behavior and mood in some studies.[3] [5]
References
- ↑ Orrego F, Villanueva S (October 1993). "The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization". Neuroscience. 56 (3): 539–55. doi:10.1016/0306-4522(93)90355-j. PMID 7902967.
- ↑ Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (April 2003). "Memantine in moderate-to-severe Alzheimer's disease". N Engl J Med. 348 (14): 1333–41. doi:10.1056/NEJMoa013128. PMID 12672860.
- ↑ 3.0 3.1 Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (April 1997). "A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study". N Engl J Med. 336 (17): 1216–22. doi:10.1056/NEJM199704243361704. PMID 9110909.
- ↑ Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (January 2014). "Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial". JAMA. 311 (1): 33–44. doi:10.1001/jama.2013.282834. PMC 4109898. PMID 24381967.
- ↑ Potter LT (1994). "Discovery of treatments for Alzheimer's disease". Neurobiol Aging. 15 Suppl 2: S67–9. doi:10.1016/0197-4580(94)90173-2. PMID 7700465.